PrecisionLife, Sano Genetics partner on studying long COVID

By The Science Advisory Board staff writers

May 12, 2022 -- PrecisionLife is joining forces with Sano Genetics to better understand the long-term effects of the coronavirus (long COVID). PrecisionLife’s proprietary combinatorial analytics platform will identify risk factors and potential drug targets by analyzing Sano Genetics’ data from 3,000 U.K. adults suffering from long COVID symptoms.

In particular, the new study seeks to determine why some people, even those with mild original COVID infections, are at risk of developing debilitating long COVID symptoms. The researchers also aim to discover novel drug targets and drug repositioning candidates with associated patient stratification biomarkers that could lead to new treatments for long COVID sufferers.

The partnership builds on support Sano Genetics received last year from the U.K. government funding body Innovate U.K. to anonymously gather genomic DNA data and patient-reported outcomes from 3,000 U.K. adults suffering from long COVID symptoms.

Copyright © 2022
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here